# Cancer Immunology Research Program

> **NIH NIH P30** · YALE UNIVERSITY · 2024 · $81,519

## Abstract

CANCER IMMUNOLOGY RESEARCH PROGRAM
PROGRAM CODE: CI
PROJECT ABSTRACT/SUMMARY
The overarching mission of the Cancer Immunology (CI) Research Program is to improve understanding of the
immune response to cancer and to discover and test novel approaches to harness the immune response to
improve patient outcomes. The Program was ranked outstanding to exceptional in the last renewal. Marcus
Bosenberg, MD, PhD, Carla Rothlin, PhD, and Mario Sznol, MD lead the CI Program and are experienced
investigators and leaders with complementary expertise, sustained NCI funding, and multiple contributions in
cancer immunology. Bosenberg has discovered new approaches for enhancing immune therapies using leading
cancer immunology models that his lab developed. Rothlin is an expert in the roles and effects of the innate
immune system on anti-cancer immune responses. Sznol is an internationally recognized expert in the clinical
evaluation of immuno-oncology therapies and pioneered the use and evaluation of combination immune
therapies. CI consists of 57 members from 17 different departments across Yale, including eight members of the
National Academy of Sciences, and nine current or former investigators/faculty of the Howard Hughes Medical
Institute. The work of the CI Program revolves around three Aims: 1) Identify mechanisms of anti-tumor immune
response and resistance; 2) Elucidate the mechanistic links between inflammation and cancer; and 3) Translate
fundamental immuno-oncology discoveries into novel therapeutic approaches and biomarkers. CI members
published 321 papers during this award period, 47% in high impact journals, with inter-programmatic (42%) and
intra-programmatic (14%) publications, demonstrating interactions among CI members within the Program, as
well as with YCC members in other programs. During the past funding period, CI experienced a 28% increase
in total funding ($17.6M direct), as well as a 46% increase in NCI funding (3.8M direct). Immune therapy for
cancer has emerged as one of the most exciting and promising new approaches ever developed to treat cancer.
YCC and the CI Program has been at the forefront of the immuno-oncology revolution, playing leading roles in
important advances in basic immunobiology, identification of checkpoint inhibitors, development of unique cancer
immunology animal models, and FDA approval of immuno-oncology therapies. CI will continue to lead this field
as a highly interactive program dedicated to improving understanding of the host response to cancer and
developing novel approaches to translate fundamental discoveries to improve cancer patient outcomes. CI will
focus on impact in YCC catchment-related malignancies, serving underrepresented populations, and training the
next generation of diverse cancer immunology researchers and translationally-focused clinicians.

## Key facts

- **NIH application ID:** 10934033
- **Project number:** 2P30CA016359-44
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** MARCUS W BOSENBERG
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $81,519
- **Award type:** 2
- **Project period:** 1997-07-01 → 2029-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10934033

## Citation

> US National Institutes of Health, RePORTER application 10934033, Cancer Immunology Research Program (2P30CA016359-44). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10934033. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*